ArticleThe Journal of biological chemistry2010
Foxp3 expression in p53-dependent DNA damage responses.
Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 62 citations in OpenAlex.
- p53: A player in the tumor microenvironment.Oncology research · 2025Review
- TP53 Codon 72 Polymorphism Impacts Macrophage Activation through Reactive Oxygen Species-Dependent Cell Signaling Alterations.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Regulation of immunological tolerance by the p53-inhibitor iASPP.Cell death & disease · 2023Article
- The Role of FOXP3 on Tumor Metastasis and Its Interaction with Traditional Chinese Medicine.Molecules (Basel, Switzerland) · 2022Review
- Article
- Epigenetic immunomodulatory effect of eugenol and astaxanthin on doxorubicin cytotoxicity in hormonal positive breast Cancer cells.BMC pharmacology & toxicology · 2021Article
- Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies.Frontiers in immunology · 2021Review
- P53: A Guardian of Immunity Becomes Its Saboteur through Mutation.International journal of molecular sciences · 2020Review
- Molecular networks of FOXP family: dual biologic functions, interplay with other molecules and clinical implications in cancer progression.Molecular cancer · 2019Review
- Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.Cancer research · 2018Article
- Long noncoding RNAs in the p53 network.Wiley interdisciplinary reviews. RNA · 2017Review
- Article
- Emerging roles of p53 and other tumour-suppressor genes in immune regulation.Nature reviews. Immunology · 2016Review
- The Double Role of p53 in Cancer and Autoimmunity and Its Potential as Therapeutic Target.International journal of molecular sciences · 2016Review
- Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53.Science (New York, N.Y.) · 2015Article
- Expression of tumoral FOXP3 in gastric adenocarcinoma is associated with favorable clinicopathological variables and related with Hippo pathway.International journal of clinical and experimental pathology · 2015Article
- Classification of Five Uremic Solutes according to Their Effects on Renal Tubular Cells.International journal of nephrology · 2014Article
- Clinical significance of FOXP3 expression in human gliomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2014Article
- A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome.Metabolic brain disease · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The forkhead transcription factor, Foxp3, is thought to act as a master regulator that controls (suppresses) expression of the breast cancer oncogenes, SKP2 and HER-2/ErbB2. However, the mechanisms that regulate Foxp3 expression and thereby modulate tumor development remain largely unexplored. Here, we demonstrate that Foxp3 up-regulation requires p53 function, showing that Foxp3 expression is directly regulated by p53 upon DNA damage responses in human breast and colon carcinoma cells. Treatment with the genotoxic agents, doxorubicin or etoposide, induced Foxp3 expression in p53-positive carcinoma cells, but not in cells lacking p53 function. Furthermore, knock down of endogenous wild-type p53 using RNA interference abrogated Foxp3 induction by genotoxic agents, and exogenous expression of p53 in cells lacking p53 restored the responsiveness of Foxp3 to DNA-damaging stresses. In addition, Foxp3 knock down blunted the p53-mediated growth inhibitory response to DNA-damaging agents. These results suggest that induction of Foxp3 in the context of tumor suppression is regulated in a p53-dependent manner and implicate Foxp3 as a key determinant of cell fate in p53-dependent DNA damage responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.